EP
ARCT icon

Essential Partners’s Arcturus Therapeutics ARCT Stock Holding History

Essential Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.99K Sell
657
-167
-20% -$1.75K ﹤0.01% 1245
2026
Q2 		$5.54K Buy
824
+488
+145% +$3.85K ﹤0.01% 1501
2026
Q1 		$2.59K Buy
336
+333
+11,100% +$2.43K ﹤0.01% 1897
2025
Q4 		$18 Buy
+3
New +$32 ﹤0.01% 2722

Other funds holding ARCT

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return

Essential Partners's ARCT Position: Q3 2026 in Review

Essential Partners reduced its Arcturus Therapeutics (ARCT) stake by 20% in Q3 2026, selling an estimated $1.75K and leaving 657 shares worth $8.99K. The position accounts for ﹤0.01% of the portfolio, ranked #1245.

Essential Partners first reported a position in ARCT in Q4 2025 and has held it in 4 quarters since. 10 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.

  • Essential Partners held 657 shares of Arcturus Therapeutics worth $8.99K as of Q3 2026.
  • Essential Partners sold 167 Arcturus Therapeutics shares in Q3 2026, an estimated $1.75K.
  • Arcturus Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1245 holding.
  • Essential Partners first reported a position in Arcturus Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 10 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.